<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745455</url>
  </required_header>
  <id_info>
    <org_study_id>SBB20R&amp;32116</org_study_id>
    <nct_id>NCT04745455</nct_id>
  </id_info>
  <brief_title>Gastrointestinal Tolerance and Safety of an Infant Formula Containing Prebiotics, Probiotics and Postbiotics.</brief_title>
  <acronym>TREE</acronym>
  <official_title>An Open-label Single-arm Study to Investigate Gastrointestinal Tolerance, Safety, and Acceptability of a New Infant Formula Containing Prebiotics, Probiotics and Postbiotics, in Healthy Term Infants.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nutricia Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nutricia Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to investigate the gastrointestinal tolerance and safety of a new formula containing&#xD;
      prebiotics, probiotics and postbiotics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Baseline</time_frame>
    <description>A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Day 7</time_frame>
    <description>A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Day 14</time_frame>
    <description>A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Day 21</time_frame>
    <description>A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Day 28</time_frame>
    <description>A 13-item questionnaire where each item is scored on a scale of 1 to 5 with higher values indicating greater GI distress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Baseline</time_frame>
    <description>Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Day 7</time_frame>
    <description>Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Day 14</time_frame>
    <description>Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Day 21</time_frame>
    <description>Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Day 28</time_frame>
    <description>Parent reported daily stool consistency using stool scales with categories 1; watery, 2; loose, 3; formed, 4; hard</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Baseline</time_frame>
    <description>Parent reported daily number of stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Day 7</time_frame>
    <description>Parent reported daily number of stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Day 14</time_frame>
    <description>Parent reported daily number of stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Day 21</time_frame>
    <description>Parent reported daily number of stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool frequency</measure>
    <time_frame>Day 28</time_frame>
    <description>Parent reported daily number of stools</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, frequency, and severity of (S)AEs, and relatedness to study product of (Serious) Adverse Events.</measure>
    <time_frame>Through study completion, an average of one month</time_frame>
    <description>(S)AE collection</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Well being questionnaire</measure>
    <time_frame>Baseline</time_frame>
    <description>A parent reported 3-item questionnaire with individual scores from 1-5 (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree)</description>
  </other_outcome>
  <other_outcome>
    <measure>Well being questionnaire</measure>
    <time_frame>Day 28</time_frame>
    <description>A parent reported 3-item questionnaire with individual scores from 1-5 (strongly agree, agree, neither agree nor disagree, disagree, strongly disagree)</description>
  </other_outcome>
  <other_outcome>
    <measure>Study product appreciation questionnaire;</measure>
    <time_frame>Day 7</time_frame>
    <description>A parent reported evaluation of product characteristics with a categorical rating scale and open questions</description>
  </other_outcome>
  <other_outcome>
    <measure>Study product appreciation questionnaire;</measure>
    <time_frame>Day 28</time_frame>
    <description>A parent reported evaluation of product characteristics with a categorical rating scale and open questions</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Gastrointestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Cow's milk based infant formula containing prebiotics, probiotics and postbiotics</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Infant formula containing prebiotics, probiotics and postbiotics</intervention_name>
    <description>Infant formula containing prebiotics, probiotics and postbiotics</description>
    <arm_group_label>Cow's milk based infant formula containing prebiotics, probiotics and postbiotics</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Term infants with a gestational age at birth of ≥37 weeks + 0 days and ≤41 weeks + 6&#xD;
             days;&#xD;
&#xD;
          2. Singleton, healthy infants as judged by the principle investigator;&#xD;
&#xD;
          3. Infants with age at screening ≥2 weeks (14 days) and ≤ 12 weeks (84 days)&#xD;
&#xD;
          4. Infants who are fully formula fed for at least 1 week prior to screening and whose&#xD;
             parents have autonomously decided to fully formula feed, i.e. not to breastfeed or&#xD;
             have ended breastfeeding, and who are intending to fully formula feed;&#xD;
&#xD;
          5. Written informed consent from the parent(s) and/or legally acceptable&#xD;
             representative(s), aged ≥ 18 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Infants who require to be fed a special diet other than standard cow's milk-based&#xD;
             infant formula;&#xD;
&#xD;
          2. Infants known to have or suspected to have cow's milk protein allergy, lactose&#xD;
             intolerance, or galactosaemia including history of any other allergic manifestations&#xD;
             or known allergy to any of the study product ingredients;&#xD;
&#xD;
          3. Infants with known or suspected congenital diseases or malformations which could&#xD;
             interfere with the study or its outcome parameters, such as but not limited to: GI&#xD;
             malformations, congenital metabolic disorders, severe congenital cardiac disorders,&#xD;
             immunodeficiency or major surgery, as per the clinical judgment of the Investigator;&#xD;
&#xD;
          4. Infants diagnosed with a gastrointestinal infection within 4 weeks prior to screening;&#xD;
&#xD;
          5. Infants with current or previous illnesses/conditions or interventions which could&#xD;
             interfere with the study or its outcome parameters (e.g. diarrhea requiring treatment,&#xD;
             constipation requiring treatment, regurgitation requiring treatment, dental/medical&#xD;
             procedures which may impact oral feeding), as per the clinical judgment of the&#xD;
             Investigator;&#xD;
&#xD;
          6. Received any of the following products/medication prior to screening: systemic&#xD;
             antibiotics, prokinetics, proton pump inhibitors, prebiotic supplements, probiotic&#xD;
             supplements, complementary feeding/weaning within 4 weeks prior to screening;&#xD;
&#xD;
          7. Incapability of infants' parents to comply with study protocol as per the judgment of&#xD;
             the Investigator (e.g. fluency in local language, access to laptop/smartphone devices&#xD;
             and internet connection required for data collection);&#xD;
&#xD;
          8. Infants with previous, current or intended participation in any other clinical study&#xD;
             involving investigational or marketed products concomitantly or prior to study.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>84 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Danone Nutricia Research</last_name>
    <phone>+31 30 2095 000</phone>
    <email>register.clinicalresearchnutricia@danone.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Poliklinika Ginekologiczno-Poloznicza Sp. Z.O.O Sp.K</name>
      <address>
        <city>Białystok</city>
        <zip>15-435</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgotorza Arciszewska, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Izabela Tarczoń Przylądek Zdrowia Specjalistyczne Poradnie Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>30-324</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Izabel Tarczon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NZLA Michalkowice Jarosz i partnerzy Spolka</name>
      <address>
        <city>Siemianowice-Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Pajek, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 12, 2021</last_update_submitted>
  <last_update_submitted_qc>February 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

